type
sm-banner
background-image
eyebrow
A Real Economy publication
title

2026 life sciences industry outlook

date
November 17, 2026
text-color
light
gradient-overlay
dark
breadcrumb

Home

Insights

Industry

Life sciences

Key takeaways

Prescription bottle icon illustration
AI can accelerate innovation and improve capital efficiency across life sciences.
Icon illustration of a cell
Adoption requires quality data, strong governance and regulatory readiness.
Medication and bottles icon illustration
AI can improve clinical development, from trial design to patient recruitment.

What is the life sciences industry outlook?

The life sciences industry continues to evolve amid shifts in innovation, technology, regulation, capital markets and the broader economic environment. RSM’s industry outlook examines the trends shaping biopharma, medtech and life sciences services companies, with a focus on what they mean for middle market organizations as they navigate change, pursue growth and position themselves for what’s ahead.

TREND 1: Artificial intelligence readiness

As AI moves from an emerging technology to a business imperative, life sciences companies that lag in adoption may risk falling behind competitors, while those that pair AI capabilities with scientific expertise, high-quality data and regulatory readiness will be better positioned to create long-term competitive advantage.

Read more

TREND 2: Medtech innovation is shifting

As medtech innovation continues to shift, companies will need to be more deliberate in how they invest in, develop and bring new devices to market. Medtech companies should prioritize capital efficiency, portfolio focus and strategic trials rather than simply increasing R&D levels.

Read more

TREND 3: Clinical trial timelines in flux

As clinical trial timelines compress in the U.S. and lengthen in the UK, life sciences companies should proactively tailor trial design, geography and funding strategies to each market’s realities.

Read more